Shamanna S. Iyengar

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Prevalence of Diagnosed and Undiagnosed Diabetes and Hypertension in India—Results from the Screening India's Twin Epidemic (SITE) Study

Shashank Joshi, Banshi Saboo, Muruga Vadivale et al. · Diabetes Technology & Therapeutics · 2011 · 161 citations · Full text

Medicine, Internal Medicine, Clinical Epidemiology +11

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Premature coronary artery disease in India: coronary artery disease in the young (CADY) registry

Shamanna S. Iyengar, R. Gupta, Saral Thangam et al. · Indian Heart Journal · 2016 · 73 citations · Full text

Medicine, Cardiology, Geriatric Medicine +17